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Abstract. The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly acquired
coinfections. Treatment or prevention of these concomitant infections often improves the quality and duration of life of
HIV-infected persons. The impact of helminth infections on infections with HIV is less clear. However, HIV is fre-
quently most problematic in areas where helminth infections are common. In advance of the widespread distribution of
drugs for elimination of lymphatic filariasis, we assessed the prevalence of active Wuchereria bancrofti infection among
HIV-positive patients in Chennai, India at two time points separated by four years. We found that the overall prevalence
of W. bancrofti infections among HIV-positive persons was 5–9.5%, and there were no quantitative differences in
circulating filarial antigen levels between HIV-positive and HIV-negative filarial-infected patients.
INTRODUCTION
The disease course of human immunodeficiency virus
(HIV) is dependent on many factors, including host, virus,
treatment, and environment. Mechanisms delaying disease
progression are of primary importance. One such strategy is
to address concomitant infections: from the beginning of the
HIV epidemic, HIV was recognized by a constellation of op-
portunistic infections that accompany advanced disease.
Through treatment and prevention of these non-HIV dis-
eases, life expectancies of HIV-infected persons are greatly
prolonged, even without specific antiretroviral treatments.
Coinfection with systemic helminths, in addition to causing
morbidity on their own, may contribute to an increased mor-
bidity from HIV. An in vitro study demonstrated that periph-
eral blood mononuclear cells from persons with actively fi-
larial infections were more susceptible to HIV infection than
were the cells from the same persons after definitive treat-
ment of their filarial infections.1 Moreover, a cross-sectional
prevalence study in Tanzania showed that people positive for
circulating antigen of Wuchereria bancrofti were more likely
to be HIV positive than persons without filarial infections.2
Although intriguing and with potential significance for HIV
control programs in filarial-endemic areas, the implications of
these findings have yet to be determined.
Few studies have examined the burden of parasitic infec-
tions in HIV-infected persons, yet it is likely to be as high or
higher than that in the general population. The latest figures
from the World Health Organization estimate that 129 mil-
lion persons worldwide are infected with W. bancrofti, Brugia
malayi, or B. timori, the major causative agents of lymphatic
filariasis, that 3.5 billion persons are infected with intestinal
helminths, and that there are 300–500 million new cases of
malaria per year. Most of this burden of disease is concen-
trated in countries where HIV incidence and prevalence are
greatest. In India, parasitic infections are endemic throughout
the country with the prevalence of hookworm infection rang-
ing between 30% and 62% (in regions around Chennai); the
prevalence of Strongyloides and Ascaris is lower.3 The preva-
lence of lymphatic filariasis, a disease caused by the nematode
W. bancrofti in southern India, is estimated to be 6–20% on
the basis of circulating filarial antigenemia.3
According to figures from the National AIDS Control Or-
ganization and the United Nations Joint Program on HIV/
AIDS,4 the estimated number of adults in India living with
HIV/acquired immunodeficiency syndrome in 2007 was
0.36% of the general population (approximately 2.5 million
people); the distribution is not uniform, with a higher preva-
lence in the southern Indian states than in northern states.
Prevalence rates among select groups, such as commercial sex
workers, persons who come to sexually transmitted disease
clinics, and intravenous drug users, are much higher and ap-
proach 10–30%.5 Use of antiretroviral drugs in the public
health system is expanding gradually in this population, with
an estimated 100,000 persons (6–15% of the population qual-
ifying for antiretroviral drugs) receiving the medications at
the end of 2006.6,7
In advance of mass drug administration for lymphatic fila-
riasis and to ultimately assess the impact of antifilarial treat-
ment on HIV/filaria coinfection in India, we conducted two
surveys four years apart in serum samples of HIV-positive
patients, looking for evidence of active filarial infection. Our
question was whether HIV-infected persons had a higher or
lower prevalence of filarial infection than HIV-negative pa-
tients in Chennai, Tamil Nadu, India.
METHODS
The Institutional Review Boards of the National Institute
of Allergy and Infectious Diseases (Bethesda, MD), the Y. R.
Gaitonde Centre for AIDS Research and Education, and the
Tuberculosis Research Center (both in Chennai, India) re-
viewed and approved this study. In 2000, 432 HIV-positive
serum samples (and for comparison a group of HIV-negative
sera from voluntarily screened patients) from the HIV clinic
at Y. R. Gaitonde Centre for AIDS Research and Education
were assessed for active filarial infection by detection of cir-
culating filarial antigen (CFA). In 2004, 200 HIV-positive sera
from patients from the HIV clinic at the Tuberculosis Re-
search Center were tested. Samples from both clinics were
well-characterized stored sera from persons referred for HIV
testing. The HIV-positive and HIV-negative samples were
from persons of the same socioeconomic status. Because
samples were de-identified, no information was available on
age, sex, or other demographic information.
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We used the W. bancrofti NOW immunochromographic
(ICT) antigen card test (Binax, Portland, ME) to determine
prevalence of filarial infection.8 To quantify antigen levels,
ICT-positive sera were analyzed using the W. bancrofti
Og4C3 antigen-capture enzyme-linked immunosorbent assay
(TropBio, James Cook University, Townsville, Queensland,
Australia) according to the manufacturer’s instructions.9 No
duplication of patients occurred between 2000 and 2004. Sta-
tistical analysis was done using the Mann-Whitney U test and
StatView™ software (Abacus, London, United Kingdom).
RESULTS
Of 432 HIV-positive patients screened in 2000, 21 (4.9%)
were positive for filarial antigen by the ICT card test. In 2004,
200 patient serum samples were screened, 19 of which were
positive by the ICT card test, resulting in an HIV/W. bancrofti
coinfection prevalence of 9.5% (Figure 1A). Prevalence of W.
bancrofti infection in HIV-positive persons did not differ sta-
tistically from that of HIV-persons (7%, n  99).
Because infection with W. bancrofti likely preceded the
acquisition of HIV, we assessed whether HIV infection influ-
enced the level or burden of filarial infection. Thus, levels of
W. bancrofti circulating antigen were quantitated in both
HIV-positive and HIV-negative persons. When filarial-
infected persons with or without HIV infections were as-
sessed by quantitative enzyme-linked immunosorbent assay
for CAg of W. bancrofti, there was no statistically significant
(P 0.07) difference in the level of filaria antigenemia in the
two groups (Figure 1B). The geometric mean (range) CAg
levels were 2,700 (217–21,080) units/mL in HIV-positive per-
sons and 3,211 (501–7,799) units/mL in HIV-negative persons.
DISCUSSION
Controlling concomitant infections that may have a detri-
mental effect on infection with HIV is imperative. Although
infection with HIV will progress and definitive antiretroviral
treatment will be necessary, the precedence for postponing
illness and death in HIV patients by controlling concomitant
infections has been well established in other coinfections. The
impact of parasitic infection, other than that with Toxoplasma
gondii, on HIV has only recently been examined. Many coun-
tries now considered epicenters of HIV transmission and dis-
ease are in tropical and subtropical areas of the world where
the burden of parasitic diseases remains highly significant.
The interaction of helminth infections with HIV has not
been completely clarified. The dominance of type 2 cytokines
present in persons with helminth infections has been postu-
lated to encourage HIV replication because immune control
of HIV requires Th1-mediated mechanisms. Some studies
have shown that patients infected with HIV and concomitant
intestinal helminth infections have decreased viral loads upon
treatment.10 Other studies have shown that patients infected
with HIV and helminths had higher CD4 cell counts, lower
viral loads, and higher CD4:CD8 ratios than did HIV-
positive, helminth-negative patients. This finding was also ob-
served in those with concomitant hookworm infections.11
Coinfection with hookworm was associated with a lower mor-
tality rate in HIV-positive patients.12 Another study demon-
strated that hookworm-infected patients were less likely to
become infected with HIV than hookworm-negative pa-
tients.2
Few studies have examined the interaction of filarial infec-
tion with HIV. In two small studies of coinfection with On-
chocerca volvulus and HIV, those infected with HIV had
more significant onchocercal skin disease13 and were less
likely to have antibodies in response to onchocercal anti-
gens.14 In vitro studies showed that peripheral blood mono-
nuclear cells from filarial-infected persons were more suscep-
tible to HIV infection, and this susceptibility decreased once
the patients were treated for their filarial infection.1 One re-
cent study that examined the prevalence of HIV and parasitic
coinfections in Tanzania found that filarial antigen positivity
was a positive predictor of HIV infection.2 When persons
HIV positive and CFA positive were compared with persons
who were HIV-negative and CFA positive, there was no dif-
ference in levels of CFA. Presence of filarial antigen did not
affect HIV viral load, CD4 cell count, or CD4%.15 When a
small subset of HIV-positive persons was treated with dieth-
ylcarbamazine, 12 weeks after treatment there was a statisti-
cal difference in HIV viral load between CFA-positive and
CFA-negative volunteers.16 Both in vitro and in vivo findings,
if they can be shown to have wider applications, may have an
impact on the Global Program to Eliminate Lymphatic Fila-
riasis, as well as the National HIV control programs.
FIGURE 1. A, Filarial antigen-positive sera in total number of sera
positive for human immunodeficiency virus (HIV) tested, by year.
The gray bars represent percentages that were filarial antigen positive
within the total number of sera tested. B, Filarial antigen levels by
detected by enzyme-linked immunosorbent assay in HIV-negative
and HIV-positive persons. The bar in the center represents the me-
dian and each circle represents an individual patient.
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We attempted to determine the coprevalence of HIV and
filarial infection in an area where filaria are endemic, and
HIV is a growing problem. We found that the rate of filarial
infection is similar to that reported in the general population
(6–10%). Moreover, at a quantitative level, filarial antigen-
emia did not differ between HIV-positive and HIV-negative
filarial infected groups. Because of the mass drug administra-
tion programs to interrupt transmission of filarial infections, it
is important to know the effect of antifilarial treatment on
HIV viral loads and disease progression. This question is be-
ing addressed in a prospective, case-controlled study of HIV/
filarial coinfection.
Received December 10, 2007. Accepted for publication May 31,
2008.
Financial support: This study was supported by the Division of In-
tramural Research, National Institute of Allergy and Infectious Dis-
eases, National Institutes of Health (Bethesda, MD).
Disclaimer: None of the authors have any conflicts of interest.
Authors’ addresses: Kawsar R. Talaat, Center for Immunization Re-
search, Department of International Health, Johns Hopkins
Bloomberg School of Public Health, Hampton House Room 249, 624
North Broadway, Baltimore, MD 21205, Tel: 410-502-9627, Fax: 410-
502-9627, E-mail: ktalaat@jhsph.edu. Nagalingaswaren Kumarasamy,
Y. R. Gaitonde Centre for AIDS Research and Education, Voluntary
Health Services, Tharamani, Chennai, India, Tel: 91-44-2254-2929,
Fax: 91-44-2254-2949, E-mail: kumarasamy@yrgcare.org. Soumya
Swaminathan, Tuberculosis Research Centre, Indian Council of
Medical Research, Spur Tank Road, Chetput, Chennai, India, Tel:
91-44-2836-9500/9624, Fax: 91-44-2836-2525, E-mail: doctorsoumya@
yahoo.com. Ramya Gopinath, Howard County General Hospital, In-
fectious Disease Associates, 11055 Little Patuxent Parkway, Colum-
bia, MD 21044, Tel: 410-884-1311, E-mail: ragopinath@yahoo.com.
Thomas B. Nutman, Laboratory of Parasitic Diseases. National In-
stitute of Allergy and Infectious Diseases, National Institutes of
Health, Building 4, Room B1-05, 4 Center Drive, Bethesda, MD
20892, Tel: 301-496-5399, Fax: 301-480-3757, E-mail: tnutman@
niaid.nih.gov.
REFERENCES
1. Gopinath R, Ostrowski M, Justement SJ, Fauci AS, Nutman TB,
2000. Filarial infections increase susceptibility to human im-
munodeficiency virus infection in peripheral blood mono-
nuclear cells in vitro. J Infect Dis 182: 1804–1808.
2. Nielsen NO, Simonsen PE, Magnussen P, Magesa S, Friis H,
2006. Cross-sectional relationship between HIV, lymphatic fil-
ariasis and other parasitic infections in adults in coastal north-
eastern Tanzania. Trans R Soc Trop Med Hyg 100: 543–550.
3. Lipner EM, Gopi PG, Subramani R, Kolappan C, Sadacharam K,
Prevots DR, Narayanan PR, Nutman TB, Kumaraswami V,
2006. Coincident filarial, intestinal helminth, and mycobacte-
rial infection: helminths fail to influence tuberculin reactivity,
but BCG influences hookworm prevalence. Am J Trop Med
Hyg 74: 841–847.
4. UNAIDS. Press Release: 2.5 Million People Living with HIV in
India. Available at: http://www.unaids.org/en/MediaCentre/
PressMaterials/FeatureStory/20070704_India_new_data.asp.
Accessed August 20, 2007.
5. Steinbrook R, 2007. HIV in India—A complex epidemic. N Engl
J Med 356: 1089–1093.
6. WHO, UNAIDS, UNICEF, 2007. Towards Universal Access:
Scaling up Priority HIV/AIDS Interventions in the Health Sec-
tor. Progress Report. Geneva: World Health Organization, 53.
7. NACO, 2007. Number of Patients on ART Cross 1 Lakh Mark.
NACO News 3(3): 3. Available at: http://www.nacoonline.org/
Quick_Links/Publication/NewsLetter/. Accessed on Decem-
ber 5, 2007.
8. Weil GJ, Lammie PJ, Weiss N, 2007. The ICT filariasis test: a
rapid format antigen test for diagnosis of Bancroftian filariasis.
Parasitol Today 13: 401–404.
9. More SJ, Copeman DB, 1990. A highly specific and sensitive
monoclonal antibody-based ELISA for the detection of circu-
lating antigen in Bancroftian filariasis. Trop Med Parasitol 41:
403–406.
10. Wolday D, Mayaan S, Mariam ZG, Berhee N, Seboxa T, Britton
S, Galai N, Landay A, Bentwich Z, 2002. Treatment of intes-
tinal worms is associated with decreased HIV plasma viral
load. J Acquir Immune Defic Syndr 31: 56–62.
11. Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich
Z, Vermund SH, 2005. Treatment of intestinal helminths does
not reduce plasma concentrations of HIV-1 RNA in coinfected
Zambian adults. J Infect Dis 192: 1277–1283.
12. Brown M, Kizza M, Watera C, Quigley MA, Rowland S, Hughes
P, Whitworth JA, Elliott AM, 2004. Helminth infection is not
associated with faster progression of HIV disease in coinfected
adults in Uganda. J Infect Dis 190: 1869–1879.
13. Kipp W, Bamuhiiga J, Rubaale T, 2003. Simulium neavei-
transmitted onchocerciasis: HIV infection increases severity of
onchocercal skin disease in a small sample of patients. Trans R
Soc Trop Med Hyg 97: 310–311.
14. Tawill SA, Gallin M, Erttmann KD, Kipp W, Bamuhiiga J, Butt-
ner DW, 1996. Impaired antibody responses and loss of reac-
tivity to Onchocerca volvulus antigens by HIV-seropositive on-
chocerciasis patients. Trans R Soc Trop Med Hyg 90: 85–89.
15. Nielsen NO, Friis H, Magnussen P, Krarup H, Magesa S, Sim-
ponsen PE, 2007. Co-infection with subclinical HIV and
Wuchereria bancrofti, and the role of malaria and hookworms,
in adult Tanzaniains: infection intensities, CD4/CD8 counts
and cytokine responses. Trans R Soc Trop Med Hyg 101: 602–
612.
16. Nielsen NO, Simonsen PE, Dalgaard P, Krarup H, Magnussen P,
Magesa S, Friis H, 2007. Effect of diethylcarbamazine on HIV
load, CD4%, and CD4/CD8 ratio in HIV-infected adult Tan-
zanians with or without lymphatic filariasis: randomized
double-blind and placebo-controlled cross-over trial. Am J
Trop Med Hyg 77: 507–513.
TALAAT AND OTHERS560
